Usynova Pharmaceuticals Ltd.

This study tests an experimental oral drug called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 adults will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.

This early-stage study tests a new tablet called UA026 to see if it is safe and how the body processes it. It involves 124 people, including healthy volunteers and those with moderate to severe plaque psoriasis. The study is split into four parts to check different doses and the …